Subscribe to RSS

DOI: 10.1055/s-0044-1800857
Assessing Epilepsy Treatment Adherence and Factors Contributing to Adherence among People with Epilepsy in Paung Township
Funding None.

Abstract
Objective This study evaluates medication adherence among epilepsy patients at public health facilities in Paung Township, Mon State, Myanmar, using both quantitative and qualitative methods to explore influencing factors.
Materials and Methods This cross-sectional study in Paung Township involved 72 epilepsy patients aged 12 years and older, receiving antiseizure medications for at least 6 months. Quantitative data were collected through questionnaires and the Morisky Medication Adherence Scale (MMAS-8), while qualitative insights were obtained from three focus group discussions involving patients and family members.
Results The study involved 72 people with epilepsy (PWE) in Paung Township, Myanmar, examining baseline characteristics, treatment services, perceptions, and adherence. The majority were young adults, and 87.5% lived in rural areas. Phenobarbital was the primary medication, and 94.4% received free medications. Most reported >50% seizure reduction and 75% attended follow-ups regularly. Overall, 59.7% demonstrated high adherence. Negative attitudes toward missing medication were prevalent among 90.3% of patients, and this was significantly associated with high adherence (p < 0.05). Family support (97.2%) and the convenience of accessing health facilities for medication were widely reported but did not show a significant association with the level of medication adherence. The qualitative findings affirmed satisfaction with health care services, minimal transportation challenges, reduced seizures, manageable side effects, and strong family support. Regular follow-ups significantly predicted adherence.
Conclusion Medication adherence among epilepsy patients in Paung Township was assessed using the MMAS-8, revealing high adherence in nearly 60% of participants. Regular follow-up appointments were significantly correlated with adherence, while negative attitudes toward missed doses and side effects influenced adherence. Patients expressed satisfaction with free medication services, convenience, and reduced seizure frequency.
Note
The MMAS-8 score, content, name, and trademarks are protected by the U.S. copyright and trademark laws. Permission for the use of the scale and its coding is required. A license agreement is available from MMAR, LLC., Donald E. Morisky, ScD, ScM, MSPH, 294 Lindura Ct., United States; dmorisky@gmail.com.
Publication History
Article published online:
20 December 2024
© 2024. Indian Epilepsy Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 International League against Epilepsy. Definition of Epilepsy 2014 . Assessed November 1, 2024 at: https://www.ilae.org/guidelines/definition-and-classification/definition-of-epilepsy-2014
- 2 Ali A. Global health: epilepsy. Semin Neurol 2018; 38 (02) 191-199
- 3 Neligan A, Hauser WA, Sander JW. The epidemiology of the epilepsies. Handb Clin Neurol 2012; 107: 113-133
- 4 Beghi E, Giussani G, Nichols E. et al; GBD 2016 Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18 (04) 357-375
- 5 Singh A, Trevick S. The epidemiology of global epilepsy. Neurol Clin 2016; 34 (04) 837-847
- 6 Department of Public Health, Department of Medical Services. Annual Hospital Statistics Report. 2013 . Ministry of Health and Sports, Nay Pyi Taw. December 2015
- 7 Cho MM, Tun N. Profile of neurological practice in Myanmar. Neurol Asia 2007; 12: 53-55
- 8 World Health Organization. Myanmar Epilepsy Initiative: Piloting the WHO Programme on Reducing the Epilepsy Treatment Gap 2013–2017. Geneva: World Health Organization; 2018
- 9 Meinardi H, Scott RA, Reis R, Sander JW. ILAE Commission on the Developing World. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia 2001; 42 (01) 136-149
- 10 Department of Medical Services. National list of essential medicines (NLEM) 2016. Ministry of Health and Sports, Nay Pyi Taw. 2016 . Available at: https://www.mohs.gov.mm/page/5491
- 11 Thit WM, Oo S, Tun N, Htoon PT. Review of epilepsy situation in Myanmar and achievements of Myanmar Epilepsy Initiative, 2014–2017. Myanmar Med J. 2019; 61 (01) 66-75 . Accessed November 20, 2024 at: https://www.mmacentral.org/publications/myanmar-medical-journal/archives-2/
- 12 Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat 2007; 3 (01) 117-131
- 13 Paschal AM, Rush SE, Sadler T. Factors associated with medication adherence in patients with epilepsy and recommendations for improvement. Epilepsy Behav 2014; 31: 346-350
- 14 Rosenfeld WE, Bramley TJ, Meyer KL. Patient compliance with topiramate vs. other antiepileptic drugs: a claims database analysis. Epilepsia 2004; 45 (Suppl. 07) 238
- 15 Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002; 3 (04) 338-342
- 16 Hugtenburg JG, Timmers L, Elders PJ, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Prefer Adherence 2013; 7: 675-682
- 17 Stewart SJ, Moon Z, Horne R. Medication nonadherence: health impact, prevalence, correlates and interventions. Psychology & health 2023; 38 (06) 726-765
- 18 Kyngäs H. Predictors of good compliance in adolescents with epilepsy. Seizure 2001; 10 (08) 549-553
- 19 Chapman SC, Horne R, Chater A, Hukins D, Smithson WH. Patients' perspectives on antiepileptic medication: relationships between beliefs about medicines and adherence among patients with epilepsy in UK primary care. Epilepsy Behav 2014; 31: 312-320
- 20 Johnbull O, Farounbi B, Adeleye A, Ogunrin O, Uche A. Evaluation of factors influencing medication adherence in patients with epilepsy in rural communities of Kaduna State, Nigeria. Neurosci Med 2011; 2: 299-305
- 21 Ahmad N, Othaman NI, Islahudin F. Medication adherence and quality of life in epilepsy patients. Int J Pharma Sci 2013; 5 (Suppl. 02) 401-403
- 22 Permatananda PA, Apsari PI, Harkitasari S. Medication adherence and quality of life among epilepsy patients: a cross sectional study. Int J Res Granth 2019; 7 (03) 1-10
- 23 Yang A, Wang B, Zhu G. et al. Validation of Chinese version of the Morisky medication adherence scale in patients with epilepsy. Seizure 2014; 23 (04) 295-299
- 24 Sweileh WM, Ihbesheh MS, Jarar IS. et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav 2011; 21 (03) 301-305
- 25 Hasiso TY, Desse TA. Adherence to treatment and factors affecting adherence of Epileptic patients at Yirgalem General Hospital, Southern Ethiopia: a prospective cross-sectional study. PLoS One 2016; 11 (09) e0163040
- 26 Huber R, Weber P. Is there a relationship between socioeconomic factors and prevalence, adherence and outcome in childhood epilepsy? A systematic scoping review. Eur J Paediatr Neurol 2022; 38: 1-6
- 27 Gurumurthy R, Chanda K, Sarma G. An evaluation of factors affecting adherence to antiepileptic drugs in patients with epilepsy: a cross-sectional study. Singapore Med J 2017; 58 (02) 98-102
- 28 Getnet A, Woldeyohannes SM, Bekana L. et al. Anti-epileptic drug nonadherence and its predictors among people with epilepsy. Behav Neurol 2016; 2016: 3189108
- 29 Shumet S, Wondie M, Ayano G, Asfaw H, Kassew T, Mesafint G. Antiepileptic drug adherence and its associated factors among epilepsy patients on follow-ups at Amanuel Mental Specialized Hospital, Ethiopia. Ethiop J Health Sci 2022; 32 (05) 913-922
- 30 Sabaté E. , editor. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003
- 31 Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic drug regimes. Seizure 1997; 6 (02) 87-93
- 32 Ettinger AB, Good MB, Manjunath R, Edward Faught R, Bancroft T. The relationship of depression to antiepileptic drug adherence and quality of life in epilepsy. Epilepsy Behav 2014; 36: 138-143
- 33 Guo Y, Ding X-Y, Lu R-Y. et al. Depression and anxiety are associated with reduced antiepileptic drug adherence in Chinese patients. Epilepsy Behav 2015; 50: 91-95
- 34 Piette JD, Richardson C, Valenstein M. Addressing the needs of patients with multiple chronic illnesses: the case of diabetes and depression. Am J Manag Care 2004; 10 (2 Pt 2): 152-162
- 35 Tedla YG, Bautista LE. Drug side effect symptoms and adherence to antihypertensive medication. Am J Hypertens 2016; 29 (06) 772-779